PostEra is using our Protonplatform to develop cures for diseases via an internal drug discovery pipeline and also through co-discovery with external partners.
The PostEra Pipeline
| Indication | Early Discovery | Late Discovery | IND-Enabling | Clinic | Partner | Rights |
|---|---|---|---|---|---|---|
COVID | Moonshot | Non-Profit | ||||
Undisclosed | Pfizer | Royalties + Milestones | ||||
Pandemic Preparedness | NIH | Non-Profit | ||||
Undisclosed | INTERNAL | 100% Owned | ||||
Oncology | Pfizer | Royalties + Milestones | ||||
Undisclosed | INTERNAL | 100% Owned | ||||
Undisclosed | INTERNAL | 100% Owned | ||||
Pandemic Preparedness | NIH | Non-Profit | ||||
CO-DISCOVERY
We partner with organizations to develop small molecule drug candidates.
Here’s how we typically work
01
Biopharma partner selects biological targets and helps define the assay cascade and Target-Product-Profile.
02
PostEra drives the discovery of safe and effective small molecules against those targets until the nomination of Development Candidate(s).
03
The Partner and PostEra agree on who shall sponsor the asset into IND-enabling studies and the Clinic.
Our Drug Discovery Partners
